Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More support for angioplasty vs thrombolysis

This article was originally published in Clinica

Executive Summary

Mortality is lower among heart attack patients treated with primary angioplasty than among those who receive thrombolytic therapy, unless the hospital only performs a low volume of angioplasties, in which case there is no difference between the two groups. This is the conclusion of a 62,299-patient retrospective cohort study based at Colorado Permanente Medical Group and the University of Colorado Health Sciences Center in Denver, which was published in the December 27 issue of the Journal of the American Medical Association. The findings of the study will fuel the continuing debate about which type of treatment is more appropriate.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT069518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel